ARNO THERAPEUTICS INC(NDA) Inactive Instrument
Arno Therapeutics Inc(NDA) Stock OTC Bulletin Board
Equities
US0425641042
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 2017 | Arno Therapeutics, Inc. Terminates Licensing Agreement with Ohio State University | CI |
| 2017 | Arno Therapeutics Seeks Acquisitions | CI |
Financials (USD)
| Sales 2014 | - | Sales 2015 | - | Capitalization | 7.04M |
|---|---|---|---|---|---|
| Net income 2014 | 7M | Net income 2015 | -11M | EV / Sales 2014 | - |
| Net cash position 2014 | 7.94M | Net Debt 2015 | 2.03M | EV / Sales 2015 | - |
| P/E ratio 2014 |
2.15
x | P/E ratio 2015 |
-0.61
x | Employees | - |
| Yield 2014 * |
-
| Yield 2015 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
Arno Therapeutics, Inc. is an early-stage company focused on developing products for the treatment of cancer and other life threatening diseases. The Company's product development pipeline includes Onapristone, AR-42, and AR-12 and analogs. Onapristone is indicated for endometrial, prostate and breast cancer indications. AR-42 is provided for hematological malignancies and solid tumors indications. AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets. Onapristone is a type 1 anti-progestin hormone blocker that has considerable anti-tumor activity in patients with breast cancer. The Company is engaged in developing and commercializing AR-42, which is an oral cancer therapy in early clinical development. AR-42 is a spectrum deacetylase inhibitor of both histone and non-histone proteins, which has potency and activity in solid tumors and hematological malignancies. AR-12 is an orally available cancer treatment.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -2.86% | 87.37B | |
| +4.08% | 41.01B | |
| -25.35% | 28.08B | |
| +54.31% | 24.72B | |
| -4.52% | 17.47B | |
| -42.09% | 11.69B | |
| -17.77% | 11.6B | |
| -12.10% | 11.56B | |
| +1.57% | 8.44B |
